HCMT
BCRX icon

Highland Capital Management (Texas)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Highland Capital Management (Texas)’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-92,680
Closed -$675K – 195
2013
Q3 		$675K Buy
+92,680
New +$470K 0.04% 126

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Highland Capital Management (Texas)'s BCRX Position: Q4 2013 in Review

Highland Capital Management (Texas) sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2013, closing a stake of 92,680 shares — an estimated $675K sold.

Highland Capital Management (Texas) first reported a position in BCRX in Q3 2013 and held it in 1 quarter. The position peaked at $675K in Q3 2013. 75 funds tracked by Wall St. Rank hold BCRX as of Q4 2013.

  • Highland Capital Management (Texas) reported no remaining BioCryst Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Highland Capital Management (Texas) sold 92,680 BioCryst Pharmaceuticals shares in Q4 2013, an estimated $675K.
  • Highland Capital Management (Texas) first reported a position in BioCryst Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Highland Capital Management (Texas)'s BioCryst Pharmaceuticals position peaked at $675K in Q3 2013.
  • 75 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2013.

Based on Highland Capital Management (Texas)'s 13F filing for Q4 2013, filed 14 Feb 2014.